Tevogen (TVGN) Capital Expenditures (2023)
Tevogen's (TVGN) quarterly Capital Expenditures came in at $133000.0 in Q1 2023.
Powered by 
Analysis
Tevogen (TVGN) Capital Expenditures (2023) Analysis & Trends
Tevogen (TVGN) has reported Capital Expenditures for 1 consecutive years, with $133000.0 the latest figure, recorded in Q1 2023.
- For the quarter ending Q1 2023, Capital Expenditures changed N/A year-over-year to $133000.0; the trailing twelve-month figure through Dec 2023 stood at $133000.0 (changed N/A YoY), and the FY2025 full-year result was $64439.0, changed N/A from the prior year.
- Capital Expenditures steadied at $133000.0 in Q1 2023 per TVGN's latest filing.
- Across five years, Capital Expenditures topped out at $133000.0 in Q1 2023 and bottomed at $133000.0 in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 3.57 Mn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | 648,000.00 |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | 5.44 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | -7.50 Mn |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 472,000.00 |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | 2.41 Mn |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 392,000.00 |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 555,000.00 |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 1.73 Mn |
| 10 | Tevogen | 27.76 Mn | 27.76 Mn | - | - |